XTL Biopharmaceuticals Ltd. — FY2023 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter filing; the supplied text does not provide separate Q4 results. Financial statements are audited and prepared under IFRS in U.S. dollars. The auditor issued an unqualified opinion and reported no critical audit matters.
Business context
XTL is a development-stage biopharmaceutical company with no product sales. Its main asset is hCDR1, a Phase II-ready candidate for systemic lupus erythematosus (SLE) and Sjögren’s syndrome (SS). The company has paused clinical-trial spending pending adequate funding or a strategic partner and is also seeking additional assets. It reported no employees and four part-time service providers as of April 30, 2024.
Financial performance and position
| Metric (US$ thousands, except per-share data) | FY2023 | FY2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | 31 | 30 |
| General and administrative expense | 734 | 850 |
| Operating loss | (765) | (880) |
| Net finance expense | (1,017) | (468) |
| Net loss | (1,782) | (1,348) |
| Basic loss per share (US$) | (0.003) | (0.002) |
| Net cash used in operating activities | (707) | (901) |
| Cash and cash equivalents at year-end | 1,401 | 2,094 |
| Marketable securities at year-end | 605 | 1,627 |
| Working capital | 1,840 | 3,619 |
| Total assets | 2,426 | 4,186 |
| Total liabilities | 206 | 187 |
| Total equity | 2,220 | 3,999 |
There is no meaningful revenue or gross margin to report. The company reported no long-term liabilities and no credit facilities; accounts payable were its reported current liabilities. Cash flow from investing activities was positive US$41 thousand, primarily interest received, and financing cash flow was nil. Cash and cash equivalents plus marketable securities totaled US$2.006 million at year-end.
Material changes versus FY2022
- Operating loss narrowed by US$115 thousand, as G&A expense fell US$116 thousand, mainly due to lower patent and insurance costs. R&D remained minimal and broadly flat.
- Net loss increased by US$434 thousand. A US$1.022 million fair-value loss on the InterCure investment and the absence of the prior-year US$1.054 million warrant revaluation gain contributed to the deterioration; net finance expense was US$549 thousand higher.
- Operating cash use decreased by US$194 thousand, but year-end cash declined US$693 thousand and working capital fell US$1.779 million. InterCure securities declined in fair value from US$1.627 million to US$605 thousand.
Outlook, risks and unusual items
- Funding and outlook: Management estimated that year-end cash and cash equivalents could fund planned activities for at least 12 months from the report date. The company expects further losses and negative operating cash flow in 2024 and beyond. Clinical-trial plans depend on financing or collaboration; additional capital may dilute shareholders or require the company to reduce development or license assets.
- Proposed Social Proxy transaction: A March 2024 term sheet proposes acquiring Social Proxy, an AI web-data company, in exchange for shares representing 44.6% of XTL after issuance and US$430 thousand in cash, with potential additional milestone securities. The proposal remained subject to due diligence, definitive agreements and other closing conditions. A related US$1.5 million private placement, also conditional on transaction closing, would issue 1.5 million units, each comprising one ADS and one five-year warrant exercisable at US$1.20. Shareholder approval was reported as obtained on April 30, 2024. XTL also advanced Social Proxy a secured US$150 thousand loan at 8% annual interest in March 2024; repayment terms permit installments over 18 months after the repayment date.
- hCDR1 development and license: Teva’s prior Phase II PRELUDE trial missed its primary SLEDAI endpoint, though the filing describes favorable secondary BILAG findings at a dose proposed for future study. XTL has not funded a new trial. The Yeda license’s Phase II commencement milestone remains unmet; Yeda may terminate on 45 days’ notice, and discussions over amended payment terms had not produced an agreement. The filing also reports that key hCDR1 patent families expired in 2022 and January 2024.
- Valuation and currency risks: The InterCure holding is measured at fair value through profit or loss, making reported earnings sensitive to share-price movements. The company also has exposure to NIS currency movements and Israeli inflation.
- Israel and listing: Management said the Israel conflict had not disrupted operations through the report date, but warned that escalation could affect operations and fundraising. XTL received a Nasdaq minimum-bid-price deficiency notice in October 2023 and reported regaining compliance on April 2, 2024.
- Controls: Management concluded that disclosure controls and internal control over financial reporting were effective at December 31, 2023. A previously identified material weakness involving warrant classification was reported as remediated.
Most important facts for investors to verify
- Whether the Social Proxy acquisition and related private placement closed, on what final terms, and what resulting dilution and governance changes occurred.
- Current cash runway, subsequent cash use, and whether additional financing or a strategic partner has been secured.
- Whether the Yeda license remains in force, whether payment terms were amended, and what steps address the missed Phase II milestone and expired patents.
- Current value and liquidity of the InterCure investment, given its substantial contribution to FY2023 losses and asset decline.
- Current Nasdaq listing compliance and the potential operational and financing effects of developments in Israel.